Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitsutoshi Yamamoto

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Parkinsonism & Related Disorders|August 14, 2003
Practice Guidelines for Parkinson's diseaseMitsutoshi Yamamoto
Rinsho Shinkeigaku = Clinical Neurology|May 22, 2004
[Issues of practice guideline]Mitsutoshi Yamamoto
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 20, 2018
Pharmacological treatment of early Parkinson's diseaseMitsutoshi Yamamoto
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 7, 2004
[Depression in Parkinson's disease]Mitsutoshi Yamamoto
Rinsho Shinkeigaku = Clinical Neurology|December 3, 2013
[Practical guideline of Parkinson's disease in Japan: evaluation and mission of future]Mitsutoshi Yamamoto
Neurology|October 13, 2006
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control studyMitsutoshi Yamamoto, Tadahisa Uesugi, Takeo Nakayama
Expert Review of Neurotherapeutics|April 18, 2008
Dopamine agonists in Parkinson's diseaseMitsutoshi Yamamoto, Anthony H V Schapira
Journal of Parkinson'S Disease|April 11, 2016
Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson's DiseaseMasaaki Hirayama, Makoto Tsunoda, Mitsutoshi Yamamoto, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled studyYoshikuni Mizuno, Kazuko Hasegawa, Tomoyoshi Kondo, et al.
The Lancet. Neurology|August 28, 2009
A reassessment of risks and benefits of dopamine agonists in Parkinson's diseaseAngelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Parkinsonism & Related Disorders|August 14, 2003
Practice Guidelines for Parkinson's diseaseMitsutoshi Yamamoto
Rinsho Shinkeigaku = Clinical Neurology|May 22, 2004
[Issues of practice guideline]Mitsutoshi Yamamoto
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 20, 2018
Pharmacological treatment of early Parkinson's diseaseMitsutoshi Yamamoto
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 7, 2004
[Depression in Parkinson's disease]Mitsutoshi Yamamoto
Rinsho Shinkeigaku = Clinical Neurology|December 3, 2013
[Practical guideline of Parkinson's disease in Japan: evaluation and mission of future]Mitsutoshi Yamamoto
Neurology|October 13, 2006
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control studyMitsutoshi Yamamoto, Tadahisa Uesugi, Takeo Nakayama
Expert Review of Neurotherapeutics|April 18, 2008
Dopamine agonists in Parkinson's diseaseMitsutoshi Yamamoto, Anthony H V Schapira
Journal of Parkinson'S Disease|April 11, 2016
Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson's DiseaseMasaaki Hirayama, Makoto Tsunoda, Mitsutoshi Yamamoto, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled studyYoshikuni Mizuno, Kazuko Hasegawa, Tomoyoshi Kondo, et al.
The Lancet. Neurology|August 28, 2009
A reassessment of risks and benefits of dopamine agonists in Parkinson's diseaseAngelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, et al.
Pageof 4